EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations

Saved in:
Bibliographic Details
Published in:Value in health 2023-12, Vol.26 (12), p.S60
Main Authors: Chueh, C.H., Ho, P.K., Chiang, S.T., Wen, Y.W., M.N., Shiu, Liu, J.H., Li, W.H., Tsai, Y.W.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
DOI:10.1016/j.jval.2023.09.328